• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Heterologous versus homologous triple anti-COVID-19 vaccine regimens in patients on maintenance haemodialysis.

作者信息

Meijers Björn, Goedgezelschap Annelien, Peeters Domien, Van Der Veen Annelien, Verbinnen Margo, Vermeersch Pieter, Stas Koen, Kuypers Dirk

机构信息

Nephrology and Transplantation Unit, University Hospitals Leuven, Leuven, Belgium.

Laboratory of Nephrology, KU Leuven, Leuven, Belgium.

出版信息

Nephrol Dial Transplant. 2022 Jun 23;37(7):1384-1386. doi: 10.1093/ndt/gfac033.

DOI:10.1093/ndt/gfac033
PMID:35138374
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9383434/
Abstract
摘要

相似文献

1
Heterologous versus homologous triple anti-COVID-19 vaccine regimens in patients on maintenance haemodialysis.维持性血液透析患者中异源与同源三联抗COVID-19疫苗接种方案
Nephrol Dial Transplant. 2022 Jun 23;37(7):1384-1386. doi: 10.1093/ndt/gfac033.
2
Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review.腺病毒载体疫苗和 mRNA COVID-19 疫苗异源与同源加强免疫接种程序的免疫原性和安全性：系统评价。
Infect Dis Poverty. 2022 May 13;11(1):53. doi: 10.1186/s40249-022-00977-x.
3
Time-dependent evolution of IgG antibody levels after first and second dose of mRNA-based SARS-CoV-2 vaccination in haemodialysis patients: a multicentre study.血液透析患者接种 mRNA 基于 SARS-CoV-2 疫苗后第一剂和第二剂后 IgG 抗体水平的时间依赖性演变：一项多中心研究。
Nephrol Dial Transplant. 2022 Jan 25;37(2):375-381. doi: 10.1093/ndt/gfab293.
4
Humoral response after SARS-CoV-2 vaccination in patients undergoing maintenance haemodialysis: loss of immunity, third dose and non-responders.接受维持性血液透析的患者接种新型冠状病毒2疫苗后的体液免疫反应：免疫丧失、第三剂疫苗和无反应者
Nephrol Dial Transplant. 2022 Jan 25;37(2):390-392. doi: 10.1093/ndt/gfab299.
5
High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients.mRNA 疫苗对慢性透析患者 SARS-CoV-2 具有高免疫原性。
Nephrol Dial Transplant. 2021 Aug 27;36(9):1704-1709. doi: 10.1093/ndt/gfab193.
6
Update to living systematic review on effectiveness of heterologous and homologous covid-19 vaccine regimens.关于异源和同源新冠疫苗接种方案有效性的实时系统评价更新
BMJ. 2022 Dec 6;379:o2865. doi: 10.1136/bmj.o2865.
7
Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis.评估严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗（BNT126b2）在维持性血液透析患者中的细胞免疫原性和体液免疫原性。
EBioMedicine. 2021 Sep;71:103567. doi: 10.1016/j.ebiom.2021.103567. Epub 2021 Aug 26.
8
An analysis of antibody responses and clinical sequalae of the Sinopharm HB02 COVID19 vaccine in dialysis patients in the United Arab Emirates.在阿拉伯联合酋长国，对接受透析治疗的患者接种国药控股 HB02 新冠疫苗后的抗体反应和临床后遗症进行分析。
Nephrology (Carlton). 2022 Mar;27(3):260-268. doi: 10.1111/nep.13980. Epub 2021 Oct 5.
9
Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls.血液透析患者在接种 COVID-19 mRNA 疫苗后的抗体反应明显低于健康对照者。
Nephrol Dial Transplant. 2021 Aug 27;36(9):1709-1716. doi: 10.1093/ndt/gfab179.
10
Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].不同 COVID-19 疫苗组合在健康个体中的安全性和免疫原性评估：一项随机、设盲、对照的 3 期临床试验 [PRIBIVAC] 的研究方案。
Trials. 2022 Jun 16;23(1):498. doi: 10.1186/s13063-022-06345-2.

引用本文的文献

1
Humoral immune response to an mRNA-1273 booster after chAdOx1-nCoV-19-priming among patients undergoing hemodialysis.在接受血液透析的患者中，ChAdOx1-nCoV-19 初免后对 mRNA-1273 加强针的体液免疫反应。
Tzu Chi Med J. 2023 Oct 6;35(4):343-347. doi: 10.4103/tcmj.tcmj_107_23. eCollection 2023 Oct-Dec.
2
Comparative effectiveness of two- and three-dose COVID-19 vaccination schedules involving AZD1222 and BNT162b2 in people with kidney disease: a linked OpenSAFELY and UK Renal Registry cohort study.涉及AZD1222和BNT162b2的两剂和三剂COVID-19疫苗接种方案在肾病患者中的比较效果：一项OpenSAFELY与英国肾脏注册队列的关联研究
Lancet Reg Health Eur. 2023 May 3;30:100636. doi: 10.1016/j.lanepe.2023.100636.
3
What has vaccination against COVID-19 in CKD patients taught us?接种 COVID-19 疫苗对慢性肾脏病患者有何启示？
J Nephrol. 2023 Jun;36(5):1257-1266. doi: 10.1007/s40620-023-01640-w. Epub 2023 May 4.
4
Impact of immunosuppressive treatment and type of SARS-CoV-2 vaccine on antibody levels after three vaccinations in patients with chronic kidney disease or kidney replacement therapy.免疫抑制治疗和新型冠状病毒2型疫苗类型对慢性肾脏病或肾脏替代治疗患者三次接种疫苗后抗体水平的影响
Clin Kidney J. 2022 Nov 24;16(3):528-540. doi: 10.1093/ckj/sfac249. eCollection 2023 Mar.
5
SARS-CoV-2 vaccination in haemodialysis patients: Insides from a prospective study comparing mRNA and viral vector vaccines.血液透析患者中的新型冠状病毒2型疫苗接种：一项比较信使核糖核酸疫苗和病毒载体疫苗的前瞻性研究内情
Lancet Reg Health Eur. 2022 Sep 13;21:100491. doi: 10.1016/j.lanepe.2022.100491. eCollection 2022 Oct.
6
Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients.血液透析患者接种三剂 mRNA-BNT162b2 和腺病毒载体 Ad26COVS1 异源 SARS-CoV-2 疫苗后的体液和细胞免疫应答。
Front Immunol. 2022 Jun 23;13:907615. doi: 10.3389/fimmu.2022.907615. eCollection 2022.

本文引用的文献

1
Homologous and Heterologous Covid-19 Booster Vaccinations.同源和异源 COVID-19 加强针接种。
N Engl J Med. 2022 Mar 17;386(11):1046-1057. doi: 10.1056/NEJMoa2116414. Epub 2022 Jan 26.
2
A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis.一项前瞻性观察研究，旨在验证在接受维持性血液透析的患者中接种第三剂 mRNA 疫苗的合理性、安全性和有效性。
Kidney Int. 2022 Feb;101(2):390-402. doi: 10.1016/j.kint.2021.10.040. Epub 2021 Nov 29.
3
Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.血液透析患者中 BNT162b2 和 mRNA-1273 SARS-CoV-2 疫苗的真实世界有效性和免疫原性。
J Am Soc Nephrol. 2022 Jan;33(1):49-57. doi: 10.1681/ASN.2021060778. Epub 2021 Nov 17.
4
Immunogenicity Rates After SARS-CoV-2 Vaccination in People With End-stage Kidney Disease: A Systematic Review and Meta-analysis.终末期肾病患者接种 SARS-CoV-2 疫苗后的免疫原性率：系统评价和荟萃分析。
JAMA Netw Open. 2021 Oct 1;4(10):e2131749. doi: 10.1001/jamanetworkopen.2021.31749.
5
B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients.肾移植受者接种第三剂 SARS-CoV-2 疫苗后的 B 和 T 细胞反应。
J Am Soc Nephrol. 2021 Dec 1;32(12):3027-3033. doi: 10.1681/ASN.2021070966.
6
COVID-19 Vaccine Type and Humoral Immune Response in Patients Receiving Dialysis.接受透析患者的新冠疫苗类型与体液免疫反应
J Am Soc Nephrol. 2022 Jan;33(1):33-37. doi: 10.1681/ASN.2021070936. Epub 2021 Oct 13.
7
Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients.英国血液透析患者新冠病毒疫苗接种后的中和抗体
Lancet. 2021 Sep 18;398(10305):1038-1041. doi: 10.1016/S0140-6736(21)01854-7. Epub 2021 Aug 13.
8
Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients.维持性血液透析患者对BNT162b2疫苗的抗体反应。
Kidney Int. 2021 Jun;99(6):1490-1492. doi: 10.1016/j.kint.2021.04.009. Epub 2021 Apr 20.
9
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.先前感染过 SARS-CoV-2 的个体对 BNT162b2 mRNA 疫苗的抗体反应。
Nat Med. 2021 Jun;27(6):981-984. doi: 10.1038/s41591-021-01325-6. Epub 2021 Apr 1.